Leufkens H - Search Results

1

Factors related to drug approvals: predictors of outcome?

Liberti L, Breckenridge A, Hoekman J, McAuslane N, Stolk P, Leufkens H. Liberti L, et al. Among authors: leufkens h. Drug Discov Today. 2017 Jun;22(6):937-946. doi: 10.1016/j.drudis.2017.03.003. Epub 2017 Mar 10. Drug Discov Today. 2017. PMID: 28288783 Review.

2

Fate of abstracts presented at five International Conferences on Pharmacoepidemiology (ICPE): 1995-1999.

Stolk P, Egberts AC, Leufkens HG. Stolk P, et al. Among authors: leufkens hg. Pharmacoepidemiol Drug Saf. 2002 Mar;11(2):105-11. doi: 10.1002/pds.687. Pharmacoepidemiol Drug Saf. 2002. PMID: 11998534

3

Changes in the defined daily dose; CYP2D6/CYP3A metabolism as an indicator for dose-setting problems.

Stolk P, Heerdink ER, Leufkens HG. Stolk P, et al. Among authors: leufkens hg. Eur J Clin Pharmacol. 2005 May;61(3):243-6. doi: 10.1007/s00228-005-0906-9. Epub 2005 Apr 28. Eur J Clin Pharmacol. 2005. PMID: 15864570

4

Between-country variation in the utilization of antihypertensive agents: Guidelines and clinical practice.

Stolk P, Van Wijk BL, Leufkens HG, Heerdink ER. Stolk P, et al. Among authors: leufkens hg. J Hum Hypertens. 2006 Dec;20(12):917-22. doi: 10.1038/sj.jhh.1002089. Epub 2006 Sep 21. J Hum Hypertens. 2006. PMID: 16988753

5

Rare essentials: drugs for rare diseases as essential medicines.

Stolk P, Willemen MJ, Leufkens HG. Stolk P, et al. Bull World Health Organ. 2006 Sep;84(9):745-51. doi: 10.2471/blt.06.031518. Bull World Health Organ. 2006. PMID: 17128345 Free PMC article.

6

The association between exposure to COX-2 inhibitors and schizophrenia deterioration. A nested case-control study.

Stolk P, Souverein PC, Leufkens HG, Weil JG, Egberts AC, Heerdink ER. Stolk P, et al. Among authors: leufkens hg. Pharmacopsychiatry. 2007 May;40(3):111-5. doi: 10.1055/s-2007-977714. Pharmacopsychiatry. 2007. PMID: 17541886

7

Gap in publication of comparative information on new medicines.

van Luijn JC, Stolk P, Gribnau FW, Leufkens HG. van Luijn JC, et al. Br J Clin Pharmacol. 2008 May;65(5):716-22. doi: 10.1111/j.1365-2125.2007.03092.x. Epub 2008 Feb 21. Br J Clin Pharmacol. 2008. PMID: 18294324 Free PMC article. Review.

8

Variable access to clopidogrel in a harmonized EU market.

Stolk P, Belitser SV, Leufkens HG, Heerdink ER. Stolk P, et al. Value Health. 2008 Sep-Oct;11(5):989-95. doi: 10.1111/j.1524-4733.2008.00331.x. Epub 2008 May 16. Value Health. 2008. PMID: 18489520 Free article.

9

Orphan drug development across Europe: bottlenecks and opportunities.

Heemstra HE, de Vrueh RL, van Weely S, Büller HA, Leufkens HG. Heemstra HE, et al. Drug Discov Today. 2008 Aug;13(15-16):670-6. doi: 10.1016/j.drudis.2008.05.001. Epub 2008 Jun 24. Drug Discov Today. 2008. PMID: 18583178 Review.

10

Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma.

Eichler HG, Pignatti F, Flamion B, Leufkens H, Breckenridge A. Eichler HG, et al. Among authors: leufkens h. Nat Rev Drug Discov. 2008 Oct;7(10):818-26. doi: 10.1038/nrd2664. Epub 2008 Sep 12. Nat Rev Drug Discov. 2008. PMID: 18787530 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

585 results

Search Page

Filters